Antisense Pharma presents data from trabedersen Stage I/II cancer study at ASCO 2012 The biopharmaceutical company Antisense Pharma today presents trabedersen complete data from its clinical Phase I/II study in patients with advanced pancreatic cancer, malignant melanoma or colorectal cancer at the international cancer congress ASCO 2012 in Chicago, USA silagra 100 review www.silagratablets.net .e. Suppression of antitumor immune metastasis and response. ‘Trabedersen shows excellent safety and encouraging survival outcomes in patients with advanced solid tumors’, concludes Dr. Hubert Heinrichs, Chief Medical Officer at Antisense Pharma.
They are glycoproteins macromolecules with a central proteins chain and long side chains made of polysaccharides. The altered MUC1 would be a good focus on molecule for antibodies in immunological antitumor therapy. The difficulty with this approach is certainly that such sugar-comprising compounds are totally ineffective at stimulating the disease fighting capability to create antibodies. Immunization is only effective if the vaccine is certainly anchored to an immunizing carrier proteins by means of a spacer, clarifies Kunz. This might be very easy to perform with polysaccharides, but turns out to be very complicated with glycoproteins, because the protein portion of the molecule offers many reactive groupings that are attacked in the coupling reaction.